1-3 of 3
Kathleen Dugan
Close
Sort by
Journal Articles

Phase II Trial of Darbepoetin Alfa in Myelodysplastic Syndrome (MDS): Preliminary Efficacy, Safety, and In Vitro Results.

Jason Gotlib, Sylvia Quesada, Jyoti Bhamidipati, Kamran Chaudry, Kunju Sridhar, Kathleen Dugan, Richard Stein, Germaine Tupper, Peter L. Greenberg
Journal: Blood
Blood (2004) 104 (11): 4737.
https://doi.org/10.1182/blood.V104.11.4737.4737
Published: 2004
Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD
Journal: Blood
Blood (2004) 104 (11): 874.
https://doi.org/10.1182/blood.V104.11.874.874
Published: 2004
Journal Articles

Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar): Presented in part at the American Society of Hematology meeting held in San Diego, CA, December 1997.

Ranjana Advani, Hussain I. Saba, Martin S. Tallman, Jacob M. Rowe, Peter H. Wiernik, Joseph Ramek, Kathleen Dugan, Bert Lum, Jenny Villena, Eric Davis, Elisabeth Paietta, Manuel Litchman, Branimir I. Sikic, Peter L. Greenberg
Journal: Blood
Blood (1999) 93 (3): 787–795.
https://doi.org/10.1182/blood.V93.3.787
Published: 1999